nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfacetamide—Secondary infection—Mometasone—systemic scleroderma	0.105	0.105	CcSEcCtD
Sulfacetamide—Secondary infection—Azathioprine—systemic scleroderma	0.0807	0.0807	CcSEcCtD
Sulfacetamide—Hepatic necrosis—Captopril—systemic scleroderma	0.0468	0.0468	CcSEcCtD
Sulfacetamide—Stinging—Mometasone—systemic scleroderma	0.0382	0.0382	CcSEcCtD
Sulfacetamide—Blister—Captopril—systemic scleroderma	0.0377	0.0377	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Pentoxifylline—systemic scleroderma	0.0337	0.0337	CcSEcCtD
Sulfacetamide—Blood disorder—Leflunomide—systemic scleroderma	0.0268	0.0268	CcSEcCtD
Sulfacetamide—Blood disorder—Mycophenolic acid—systemic scleroderma	0.0256	0.0256	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Azathioprine—systemic scleroderma	0.0223	0.0223	CcSEcCtD
Sulfacetamide—Dermatitis bullous—Captopril—systemic scleroderma	0.0206	0.0206	CcSEcCtD
Sulfacetamide—Blood disorder—Mycophenolate mofetil—systemic scleroderma	0.0202	0.0202	CcSEcCtD
Sulfacetamide—Dermatitis bullous—Mycophenolic acid—systemic scleroderma	0.0162	0.0162	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Mycophenolate mofetil—systemic scleroderma	0.0158	0.0158	CcSEcCtD
Sulfacetamide—Erythema—Pentoxifylline—systemic scleroderma	0.0157	0.0157	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Azathioprine—systemic scleroderma	0.0155	0.0155	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Captopril—systemic scleroderma	0.0151	0.0151	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Leflunomide—systemic scleroderma	0.0146	0.0146	CcSEcCtD
Sulfacetamide—Agranulocytosis—Captopril—systemic scleroderma	0.0142	0.0142	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Azathioprine—systemic scleroderma	0.0132	0.0132	CcSEcCtD
Sulfacetamide—Erythema multiforme—Captopril—systemic scleroderma	0.0129	0.0129	CcSEcCtD
Sulfacetamide—Dermatitis bullous—Mycophenolate mofetil—systemic scleroderma	0.0128	0.0128	CcSEcCtD
Sulfacetamide—Oedema—Pentoxifylline—systemic scleroderma	0.0128	0.0128	CcSEcCtD
Sulfacetamide—Infection—Pentoxifylline—systemic scleroderma	0.0127	0.0127	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Lisinopril—systemic scleroderma	0.0126	0.0126	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Leflunomide—systemic scleroderma	0.0124	0.0124	CcSEcCtD
Sulfacetamide—Agranulocytosis—Azathioprine—systemic scleroderma	0.0124	0.0124	CcSEcCtD
Sulfacetamide—Agranulocytosis—Leflunomide—systemic scleroderma	0.0117	0.0117	CcSEcCtD
Sulfacetamide—Erythema multiforme—Azathioprine—systemic scleroderma	0.0113	0.0113	CcSEcCtD
Sulfacetamide—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.0112	0.0112	CcSEcCtD
Sulfacetamide—Infection—Mometasone—systemic scleroderma	0.011	0.011	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Lisinopril—systemic scleroderma	0.0107	0.0107	CcSEcCtD
Sulfacetamide—Erythema multiforme—Leflunomide—systemic scleroderma	0.0106	0.0106	CcSEcCtD
Sulfacetamide—Agranulocytosis—Lisinopril—systemic scleroderma	0.01	0.01	CcSEcCtD
Sulfacetamide—Pain—Mometasone—systemic scleroderma	0.00944	0.00944	CcSEcCtD
Sulfacetamide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00943	0.00943	CcSEcCtD
Sulfacetamide—Erythema multiforme—Lisinopril—systemic scleroderma	0.00914	0.00914	CcSEcCtD
Sulfacetamide—Pruritus—Pentoxifylline—systemic scleroderma	0.00905	0.00905	CcSEcCtD
Sulfacetamide—Aplastic anaemia—Methotrexate—systemic scleroderma	0.00897	0.00897	CcSEcCtD
Sulfacetamide—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.0088	0.0088	CcSEcCtD
Sulfacetamide—Erythema—Lisinopril—systemic scleroderma	0.00841	0.00841	CcSEcCtD
Sulfacetamide—Infection—Azathioprine—systemic scleroderma	0.00841	0.00841	CcSEcCtD
Sulfacetamide—Infection—Leflunomide—systemic scleroderma	0.00794	0.00794	CcSEcCtD
Sulfacetamide—Pruritus—Mometasone—systemic scleroderma	0.00781	0.00781	CcSEcCtD
Sulfacetamide—Oedema—Mycophenolic acid—systemic scleroderma	0.00762	0.00762	CcSEcCtD
Sulfacetamide—Infection—Mycophenolic acid—systemic scleroderma	0.00757	0.00757	CcSEcCtD
Sulfacetamide—Oedema—Lisinopril—systemic scleroderma	0.00687	0.00687	CcSEcCtD
Sulfacetamide—Pruritus—Captopril—systemic scleroderma	0.00686	0.00686	CcSEcCtD
Sulfacetamide—Pain—Leflunomide—systemic scleroderma	0.00683	0.00683	CcSEcCtD
Sulfacetamide—Infection—Lisinopril—systemic scleroderma	0.00682	0.00682	CcSEcCtD
Sulfacetamide—Pain—Mycophenolic acid—systemic scleroderma	0.00652	0.00652	CcSEcCtD
Sulfacetamide—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.00624	0.00624	CcSEcCtD
Sulfacetamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00624	0.00624	CcSEcCtD
Sulfacetamide—Oedema—Mycophenolate mofetil—systemic scleroderma	0.00602	0.00602	CcSEcCtD
Sulfacetamide—Infection—Mycophenolate mofetil—systemic scleroderma	0.00598	0.00598	CcSEcCtD
Sulfacetamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00589	0.00589	CcSEcCtD
Sulfacetamide—Pain—Lisinopril—systemic scleroderma	0.00587	0.00587	CcSEcCtD
Sulfacetamide—Pruritus—Leflunomide—systemic scleroderma	0.00565	0.00565	CcSEcCtD
Sulfacetamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.00539	0.00539	CcSEcCtD
Sulfacetamide—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.0053	0.0053	CcSEcCtD
Sulfacetamide—Pain—Mycophenolate mofetil—systemic scleroderma	0.00515	0.00515	CcSEcCtD
Sulfacetamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00506	0.00506	CcSEcCtD
Sulfacetamide—Erythema—Prednisone—systemic scleroderma	0.005	0.005	CcSEcCtD
Sulfacetamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.00499	0.00499	CcSEcCtD
Sulfacetamide—Pruritus—Lisinopril—systemic scleroderma	0.00486	0.00486	CcSEcCtD
Sulfacetamide—Erythema multiforme—Methotrexate—systemic scleroderma	0.00454	0.00454	CcSEcCtD
Sulfacetamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00443	0.00443	CcSEcCtD
Sulfacetamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Sulfacetamide—Erythema—Methotrexate—systemic scleroderma	0.00418	0.00418	CcSEcCtD
Sulfacetamide—Oedema—Prednisone—systemic scleroderma	0.00408	0.00408	CcSEcCtD
Sulfacetamide—Infection—Prednisone—systemic scleroderma	0.00405	0.00405	CcSEcCtD
Sulfacetamide—Infection—Methotrexate—systemic scleroderma	0.00339	0.00339	CcSEcCtD
Sulfacetamide—Hypersensitivity—Prednisone—systemic scleroderma	0.003	0.003	CcSEcCtD
Sulfacetamide—Pain—Methotrexate—systemic scleroderma	0.00291	0.00291	CcSEcCtD
Sulfacetamide—Pruritus—Prednisone—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Sulfacetamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.00251	0.00251	CcSEcCtD
Sulfacetamide—Pruritus—Methotrexate—systemic scleroderma	0.00241	0.00241	CcSEcCtD
